Compare Ulta Beauty Inc (ULTA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ulta Beauty Inc vs Zoetis Inc — how do they compare? Ulta Beauty Inc trades at $570.37 (market cap $24.12B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ulta Beauty Inc for 92 Days and Zoetis Inc for 70 Days on average.
| ULTA | ZTS | |
|---|---|---|
Market Cap | $24.12B | $30.20B |
Volume | 457,598 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $706.82 | $147.53 |
52-Week Low | $450.75 | $69.09 |
Typical Hold Time | 92 Days | 70 Days |
Enterprise Value | $26.43B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ULTA stock trades at $570.37, up 4.56% today, reflecting strong momentum after recent earnings beats and raised 2026 guidance. The technical outlook is bullish, with the price near resistance at $572, while fundamentals show robust profitability with a 9.34% net margin and 46.12% ROE. Revenue growth is steady, reaching $11.3B in 2025, though margins face slight pressure. Analyst sentiment is positive, with a consensus price target of $624.93 and 59.57% buy ratings.
The stock presents a compelling growth opportunity supported by e-commerce acceleration and expansion into wellness categories, but risks include promotional pressures, flat store traffic, and margin compression. Execution on raised guidance and omnichannel strategy will be critical for sustaining the rally amid competitive and consumer spending headwinds.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
